
The company reported 5% revenue growth and higher adjusted earnings, then raised its full-year non-GAAP EPS guidance to $12.80-$13.00.
Cardinal Health raised its fiscal 2027 non-GAAP diluted EPS outlook to $12.80-$13.00 after reporting first-quarter revenue of $67.5 billion, up 5% year over year. Non-GAAP diluted EPS rose 28% to $3.26.
The company’s new forecast compares with its previous range of $12.40-$12.60. Cardinal Health said the updated outlook represents 17%-19% growth against its fiscal 2026 baseline excluding a tariff refund, and 14%-15% growth against reported fiscal 2026 results.
First-quarter GAAP operating earnings increased 13% to $753 million, while GAAP diluted EPS rose 27% to $2.38. The company said higher non-GAAP operating earnings, a lower share count and a lower effective tax rate contributed to adjusted EPS growth.
Pharmaceutical and Specialty Solutions revenue rose 6% to $62.6 billion, with segment profit up 17% to $783 million. Global Medical Products and Distribution revenue was $3.2 billion, roughly flat year over year, while segment profit fell 28% to $33 million.
Cardinal Health also completed a $500 million share repurchase program during the quarter. It raised its expected profit growth for Pharmaceutical and Specialty Solutions and its “Other” businesses, and lowered its expected non-GAAP effective tax rate to 18.5%-19.5%.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.